

28 Jan 2021 | News

QUOTED. 28 January 2021. Andrea Riposat.

by

L'Aquila, Italy-based Dante Laboratories company announced a £30m investment in global surveillance of new variants of the SARS-CoV-2 virus. CEO Andrea Riposat discussed the purchase.

“The SARS-CoV-2 RNA may be simpler to analyze than the human genome. Yet both require massive investments in software.” – Andrea Riposat, CEO, Dante Labs

- Find out more: [Dante Labs Invests In UK To Apply Consumer Genome Sequencing To COVID-19 Variants](#)

[Click here](#) for a free trial of *Medtech Insight*